Previous studies have shown higher mortality in children with rheumatic diseases, particularly in children with dermatomyositis and systemic lupus erythematosus, but most of these studies were small and/or dated. Studies have also demonstrated an increase in cancer incidence in children with juvenile idiopathic arthritis. Newer studies are needed to determine mortality and cancer rates in children with rheumatic diseases. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry is an ideal database to study mortality and cancer rates because it is the largest observational pediatric rheumatology research registry in the United States. We propose to link the CARRA Registry to a national death and national cancer database to calculate death and cancer rates in pediatric rheumatic diseases. We will investigate whether patient characteristics, disease type or status, and medications increase risk of death. If we identify risk factors associated with death we may be able to prevent it.